Compare ADMA Biologics Inc (ADMA) vs Under Armour Inc Class A (UA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Under Armour Inc Class A — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Under Armour Inc Class A trades at $6.35 (market cap $2.84B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and Under Armour Inc Class A is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | UA | |
|---|---|---|
Market Cap | $2.13B | $2.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $7.88 |
52-Week Low | $7.60 | $3.96 |
Enterprise Value | $2.20B | $4.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Under Armour (UA) trades at $6.64, up 2.47% with a bullish technical signal from moving averages despite bearish oscillators. The company reported mixed Q1 2026 results, missing EPS expectations after beating in previous quarters. Revenue declined to $5.0B in 2026 with a net loss of -$496M, though valuation remains reasonable with P/S of 0.57. Recent news highlights a Dodge collaboration and insider buying by Prem Watsa.
The outlook remains challenging with declining revenue and negative profitability, but analyst consensus leans positive with 40% buy ratings. Key risks include sustained revenue declines and competitive pressures, while potential catalysts include premium product focus and inventory discipline. The stock presents a turnaround opportunity with significant execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
